Free Trial

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

Viridian Therapeutics logo
$13.50 -0.43 (-3.09%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$13.74 +0.24 (+1.78%)
As of 05/28/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Key Stats

Today's Range
$13.38
$14.18
50-Day Range
$11.02
$15.46
52-Week Range
$9.90
$27.20
Volume
1.08 million shs
Average Volume
1.19 million shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.70
Consensus Rating
Moderate Buy

Company Overview

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

VRDN MarketRank™: 

Viridian Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 558th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Viridian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Viridian Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Viridian Therapeutics are expected to decrease in the coming year, from ($4.03) to ($4.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viridian Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viridian Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viridian Therapeutics has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Viridian Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.41% of the float of Viridian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viridian Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Viridian Therapeutics has recently increased by 4.25%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Viridian Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viridian Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.41% of the float of Viridian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viridian Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Viridian Therapeutics has recently increased by 4.25%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Viridian Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Viridian Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    3 people have searched for VRDN on MarketBeat in the last 30 days.
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VRDN Stock News Headlines

July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
Viridian Therapeutics appoints Ajer to its board of directors
See More Headlines

VRDN Stock Analysis - Frequently Asked Questions

Viridian Therapeutics' stock was trading at $19.17 on January 1st, 2025. Since then, VRDN shares have decreased by 29.6% and is now trading at $13.50.
View the best growth stocks for 2025 here
.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics's quarterly revenue was up .0% compared to the same quarter last year.

Viridian Therapeutics' top institutional investors include Vanguard Group Inc. (5.59%), Paradigm Biocapital Advisors LP (2.57%), Maverick Capital Ltd. (2.53%) and Alliancebernstein L.P. (2.48%). Insiders that own company stock include Fairmount Funds Management Llc, Jonathan Violin, Scott Dunseth Myers, Lara Meisner, Stephen F Mahoney, Thomas W Beetham and Barrett Katz.
View institutional ownership trends
.

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
5/28/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:VRDN
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.70
High Stock Price Target
$61.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+171.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$237.73 million
Net Margins
-85,127.16%
Pretax Margin
-85,127.16%

Debt

Sales & Book Value

Annual Sales
$302,000.00
Price / Cash Flow
N/A
Book Value
$4.48 per share
Price / Book
3.01

Miscellaneous

Free Float
78,698,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
0.57
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:VRDN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners